SCHEMBL25062385

SCHEMBL25062385

CON(C)C(=O)CCCCO[Si](c1ccccc1)(c1ccccc1)C(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.36
CYP3A4 P08684 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
SMYD2 Q9NRG4 2/20 0.34
BCHE P06276 3/20 0.33
ACHE P22303 3/20 0.33
JAK3 P52333 1/20 0.32
BTK Q06187 1/20 0.32
PDK2 Q15119 1/20 0.32
KDM4A O75164 1/20 0.32
KDM4C Q9H3R0 1/20 0.32
HDAC1 Q13547 2/20 0.32
HDAC2 Q92769 2/20 0.32
CHRM2 P08172 1/20 0.32
CHRM1 P11229 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC4 P56524 1/20 0.32
HDAC7 Q8WUI4 1/20 0.32
HDAC10 Q969S8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31528857 0.99 CYP3A4 (0.35) ALOX5CYP3A4HTTSMN1; SMN2SMYD2
SCHEMBL31528924 0.99 CYP3A4 (0.35) ALOX5CYP3A4HTTSMN1; SMN2SMYD2
SCHEMBL31528877 0.99 CYP3A4 (0.35) ALOX5CYP3A4HTTSMN1; SMN2SMYD2
SCHEMBL7604494 0.96 CYP3A4 (0.36) ALOX5CYP3A4HTTSMN1; SMN2SMYD2
SCHEMBL21801968 0.91 HTT (0.38) CYP3A4HTTSMN1; SMN2SMYD2JAK3
SCHEMBL6345426 0.83 PPARA (0.43) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL17755998 0.81 SMYD2 (0.42) CYP3A4HTTSMN1; SMN2SMYD2HDAC1
SCHEMBL5847918 0.81 LTB4R (0.41) CYP3A4HTTSMN1; SMN2SMYD2PDK2
SCHEMBL25355046 0.81 TBXA2R (0.43) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL19405748 0.81 TBXA2R (0.43) HDAC1HDAC2HDAC3HDAC4HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116234800-A Copper complexes for the treatment of neurodegenerative disorders ALS治疗发展学会 2023-06-06 CN disclosed
US-20230054997-A1 COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS ALS THERAPY DEVELOPMENT INSTITUTE, 2023-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230054997-A1 COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS SOD1, SMN1; SMN2, CLN6 ALOX5 2441/4885CYP3A4 4471/4885HTT 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.